CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07508787
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:04.315371+00:00
Published At: 2026-04-02T00:00:00+00:00
Record Updated At: 2026-04-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Renal Transplant Failure and Rejection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-02"
protocolSection.identificationModule.nctId: "NCT07508787"
protocolSection.identificationModule.officialTitle: "Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.